Financials in USD. Standardized financial statements.
A compact view of how Igene Biotechnology, Inc. turns revenue into operating income and net income.
| Metric | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2003 | FY 2002 | FY 2001 | FY 2000 | FY 1999 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.96M | $7.64M | $2.29M | $0 | $463,486 | $3.49M | $4.18M | $702,533 | $18,131 |
| Revenue Growth? | -48.2% | +234.3% | 0.0% | -100.0% | -86.7% | -16.5% | +495.1% | +3774.8% | 0.0% |
| Cost of Revenue? | $2.94M | $6.40M | $1.68M | $0 | $446,144 | $3.17M | $3.52M | $691,156 | $83,918 |
| Gross Profit? | $1.02M | $1.25M | $605,098 | $0 | $17,342 | $324,131 | $663,609 | $11,377 | -$65,787 |
| Gross Margin? | +25.7% | +16.3% | +26.5% | 0.0% | +3.7% | +9.3% | +15.9% | +1.6% | -362.8% |
| Operating Expenses? | $990,930 | $3.44M | $537,978 | $307,370 | $642,083 | $2.18M | $2.30M | $1.52M | $1.77M |
| Operating Income? | -$1.07M | -$2.19M | $237,941 | -$416,517 | -$624,741 | -$1.85M | -$1.64M | -$1.51M | -$1.84M |
| EBITDA? | -$851,286 | -$2.08M | $324,579 | -$307,516 | -$540,955 | -$1.67M | -$1.50M | -$1.41M | -$1.23M |
| Income Before Tax | -$43,227 | -$1.96M | $261,565 | -$401,982 | -$420,134 | -$2.75M | -$3.67M | -$1.55M | -$1.83M |
| Income Tax Expense | $165,380 | $1.80M | $1.97M | $848,403 | $659,906 | $0 | $0 | $745,674 | $686,190 |
| Net Income? | -$140,747 | -$3.99M | -$1.90M | -$1.16M | -$2.20M | -$3.19M | -$3.67M | -$2.26M | -$2.53M |
| EPS? | $-0.00 | $-0.02 | $-0.02 | $-0.01 | $-0.02 | $-0.04 | $-0.05 | $-0.04 | $-0.07 |
| Diluted EPS? | $-0.00 | $-0.02 | $-0.02 | $-0.01 | $-0.02 | $-0.04 | $-0.05 | $-0.04 | $-0.07 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality